0001415889-24-010432.txt : 20240405
0001415889-24-010432.hdr.sgml : 20240405
20240405165538
ACCESSION NUMBER: 0001415889-24-010432
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240403
FILED AS OF DATE: 20240405
DATE AS OF CHANGE: 20240405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MITCHELL DEAN J
CENTRAL INDEX KEY: 0001199297
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39743
FILM NUMBER: 24827213
MAIL ADDRESS:
STREET 1: C/O BRISTOL MYERS SQUIBB CO
STREET 2: 345 PARK AVE
CITY: NEW YORK
STATE: NY
ZIP: 10164
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kinnate Biopharma Inc.
CENTRAL INDEX KEY: 0001797768
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824566526
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11975 EL CAMINO REAL, STE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 8582994699
MAIL ADDRESS:
STREET 1: 11975 EL CAMINO REAL, STE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
form4-04052024_040425.xml
X0508
4
2024-04-03
1
0001797768
Kinnate Biopharma Inc.
KNTE
0001199297
MITCHELL DEAN J
800 WEST EL CAMINO REAL
SUITE 180
MOUNTAIN VIEW
CA
94040
true
false
false
false
0
Stock Option (right to buy)
5.63
2024-04-03
4
D
0
121503
D
2030-08-18
Common Stock
121503
0
D
Stock Option (right to buy)
24.46
2024-04-03
4
D
0
20250
D
2031-06-11
Common Stock
20250
0
D
Stock Option (right to buy)
8.38
2024-04-03
4
D
0
20250
D
2032-06-13
Common Stock
20250
0
D
Stock Option (right to buy)
3.48
2024-04-03
4
D
0
25000
D
2033-06-12
Common Stock
25000
0
D
This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
/s/ James P. Reilly, Attorney-in-Fact
2024-04-05